Previous close | 0.2500 |
Open | 0.2500 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.2500 - 0.2500 |
52-week range | 0.1710 - 0.3530 |
Volume | |
Avg. volume | 5,566 |
Market cap | 34.354M |
Beta (5Y monthly) | 0.23 |
PE ratio (TTM) | 12.50 |
EPS (TTM) | 0.0200 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
MISSISSAUGA, Ontario, April 11, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces it will be attending and presenting at the Bloom Burton & Co. Healthcare Investor Conference (the “Conference”) taking place at the Metro Toronto Convention Center, North Building, on April 16 and 17, 2024. The Conference provides an opportunity to connect with Canadian, U.S., and international investors who are in
MISSISSAUGA, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF) (“Microbix®” or the Company”), a life sciences innovator and exporter, announces the voting results from the Annual and Special Meeting of Shareholders of the Company (the “Meeting”) which was held on March 27, 2024. At the Meeting, 42.64% of the issued and outstanding shares were represented. Shareholders voted in favour of all resolutions brought before the Meeting. Details of all resolut
Sequel Pharma Executes Agreement with CDMO for Drug Substance ProductionMISSISSAUGA, Canada, March 14, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that its funding and commercialization partner, Sequel Pharma, LLC (“Sequel”), has executed, with support from Microbix, an agreement with a leading international contract development and manufacturing organization (“CDMO”) for production of the